← All Incyte CORP filings

Incyte CORP DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
INCY
Incyte CORP
DEF: Incyte Corporation 2026 Annual Meeting Proxy Statement
Incyte Corporation announces its 2026 Annual Meeting of Shareholders, detailing director elections, executive compensation, and auditor ratification, alongside a strong 2025 performance review.
NASDAQ
INCY
Incyte CORP
DEFA14A: Incyte Corporation Sets Date for 2025 Annual Stockholder Meeting
Incyte Corporation will hold its annual stockholder meeting on June 10, 2025, to vote on director elections, executive compensation, stock incentive plans, and the ratification of its public accounting firm.
NASDAQ
INCY
Incyte CORP
DEF 14A: Incyte Reports Strong 2024 Performance and Pipeline Progress, Eyes Key Approvals in 2025
Incyte's total revenues grew by 15% in 2024, reaching $4.2 billion, driven by Jakafi and Opzelura, with significant pipeline advancements setting the stage for a pivotal 2025.
NASDAQ
INCY
Incyte CORP
DEFA14A: Incyte Corp Issues Supplement to Proxy Statement Regarding Executive Compensation
Incyte Corporation releases a supplement to its proxy statement, clarifying details regarding the make-whole equity award granted to Dr. Pablo J. Cagnoni, President of Research and Development.
NASDAQ
INCY
Incyte CORP
DEFA14A: Incyte Corporation Sets Date for Annual Stockholder Meeting, Outlines Proposals
Incyte Corporation announces its annual stockholder meeting to be held on June 12, 2024, outlining proposals for director elections, executive compensation approval, and auditor ratification.
NASDAQ
INCY
Incyte CORP
DEF 14A: Incyte Reports Strong 2023 Growth, Advances Pipeline with Multiple Regulatory Milestones
Incyte's product and royalty revenues grew 14% to $3.7 billion in 2023, driven by Opzelura and Jakafi, with significant progress in regulatory and clinical milestones.